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Background. Sepsis is an increasingly common condition, which continues to be associated with unacceptably high
mortality. A large number of association studies have investigated susceptibility to, or mortality from, sepsis for variants in
the functionally important immune-related geneMBL2. These studies have largely been underpowered and contradictory.
Methods. We genotyped and analyzed 4 important MBL2 single nucleotide polymorphisms (SNPs; rs5030737,
rs1800450, rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsis
cases, and 477 controls from the United Kingdom. We analyzed the following predeﬁned subgroups and outcomes: 28-
day and 6monthmortality from sepsis due to CAP or peritonitis combined, 28-daymortality fromCAP sepsis, peritonitis
sepsis, pneumococcal sepsis or sepsis in younger patients, and susceptibility to CAP sepsis or pneumococcal sepsis in the
United Kingdom.
Results. There were no signiﬁcant associations (all P-values were greater than .05 after correction for multiple testing)
between MBL2 genotypes and any of our predeﬁned analyses.
Conclusions. In this large, well-deﬁned cohort of immune competent adult patients, no associations betweenMBL2
genotype and sepsis susceptibility or outcome were identiﬁed.
Keywords. mannose-binding lectin; MBL; genetics; sepsis; association study.
The incidence of sepsis is increasing and mortality rates
remain high [1]. Sepsis was recently reported to be
responsible for 1 in 20 deaths in England [2]. The
frequency of hospitalizations with severe sepsis has in-
creased relentlessly, more than doubling each year
between 2000 and 2007, with sepsis complicated by
organ failure accounting for one in 40 hospitalizations
in 2007 [3]. It has long been apparent that host genetic
factors can signiﬁcantly inﬂuence mortality from infec-
tious disease [4], but despite extensive research very few
robust associations between genetic polymorphisms and
sepsis phenotypes have been reported to date [5].Possible
explanations for these inconsistent ﬁndings include inad-
equate sample sizes (and hence a lack of study power),
unidentiﬁed population substructure, failure to correct
for multiple testing, variations in phenotype deﬁnition,
heterogeneous patient populations and unrecognized
host-pathogen interactions.Nevertheless,we recentlypub-
lished a genome-wide association study (GWAS) in
whichwe identiﬁed acommonsingle nucleotide polymor-
phism (SNP) in the FER gene that protects against death
from sepsis caused by severe pneumonia [6].
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MBL2 is one of the most extensively studied but still contro-
versial candidate genes reported to be associated with sepsis and
infectious disease phenotypes [7, 8]. More than 30 studies have
reported the presence or absence of associations between poly-
morphisms in the MBL2 gene, circulating MBL levels, and sus-
ceptibility and outcomes in sepsis phenotypes, with sample
sizes ranging from 6 to 848 patients [8–10].
The MBL2 gene encodes mannose-binding lectin, which
binds carbohydrates on the surface of a wide variety of bacteria,
viruses, yeasts, fungi, and protozoa and subsequently triggers
host innate immune responses through activation of the com-
plement system, in addition to promoting opsono-phagocytosis
by a complement-independent pathway [11]. The function of
MBL is known to be inﬂuenced by common SNPs found both
in the promoter region and in exon 1 of this gene, which affect
the level of gene expression and the structure of the MBL protein
respectively [12–18].
Three functional SNPs (denoted B-rs1800450, C-rs1800451,
and D-rs5030737) in exon 1 of MBL2 affect the stability, ligand
binding capacity, complement activating ability and half-life
of the encoded protein [12–15]. Because their effect on serum
MBL levels is very similar, wild-type alleles for these SNPs are
denoted A, whereas the B, C, and D variants are pooled and
given the designation O (Supplementary Figure 1). If an indi-
vidual is heterozygous (A/O) for any one of these 3 variants,
MBL levels are 10%–20% that of wild-type individuals, whereas
in variant homozygotes or compound heterozygotes (O/O),
serum MBL concentrations are virtually undetectable [16].
MBL2 promoter polymorphisms have also been associated
with MBL levels independent of these exonic SNPs. Allele X
of the SNP denoted X/Y at position -221 (rs7096206) has the
strongest down-regulating effect [12, 17, 18] and is therefore
the most important SNP to analyze, but some studies have
also analyzed another promoter SNP, rs11003125 [8, 19].
The aim of this study was to conﬁrm or refute an association
between commonMBL2 genetic variants and sepsis susceptibility
or outcome. We performed an association study in 1839 patients
with sepsis due to community acquired pneumonia (CAP) or
peritonitis recruited from intensive care units (ICUs) across
Europe as part of the GenOSept and GAinS collaborations and
used 477 UK controls recruited within the GRACE consortium.
To our knowledge, this is the largest study investigating the
inﬂuence of MBL2 polymorphisms on sepsis susceptibility and
survival.
METHODS
Samples
Sepsis Patients (GenOSept and GAinS Consortia)
Patients admitted to critical care units with sepsis caused by
CAP or peritonitis were recruited to the ESICM/ECCRN
GenOSept (Genetics of Sepsis and Septic Shock in Europe)
study between June 2006 and October 2009 from 143 centers
in 16 European countries. Recruitment as part of the GAinS
study (part of which was included in the GenOSept sample
set) began in September 2005 and continued in UK centers,
using the same protocol, after the GenOSept study was closed;
UK samples from patients recruited to GAinS until October
2010 were also included in this study. Ethics approval was
granted either nationally, for individual centers or both. In all
cases written, informed consent was obtained from the patient
or a legal representative. Diagnosis of sepsis was based on the
International Consensus Criteria published in 2003 [20]. Inclu-
sion criteria were adult patients (≥18 years) admitted to an ICU
or High Dependency Unit with CAP or peritonitis. The diagno-
sis of CAP was based on a febrile illness associated with cough,
sputum production, breathlessness, leukocytosis, and radiolog-
ical features of pneumonia acquired within the community or
within less than 2 days of hospital admission [21].Exclusion cri-
teria at recruitment were: pregnancy, an advanced directive to
withhold or withdraw life sustaining treatment, admission for
palliative care only, and immune-compromise. These collec-
tions are also described in more detail elsewhere [6, 22, 23].
Microbiological investigations were performed according to
local policies and practices. Investigators recorded microbiolog-
ical ﬁndings for patients diagnosed with CAP, including the
organism(s) isolated, the source of the organism and the use
of serological methods. The local investigators recorded wheth-
er or not initial antibiotic therapy (within the ﬁrst 24 hours) was
considered to be appropriate. Death or survival was recorded at
ICU discharge, hospital discharge, and 6 months from ICU
admission. The date of death was also recorded.
DNA was extracted by GenOSept partners in London and
Munich with a salting out method, in Paris with MagNA
Pure Compact DNA Isolation Kits, and in Oxford with Qiagen
Midi kits.
UK Controls (GRACE Network)
Controls were recruited as part of the GRACE network study
(www.grace-lrti.org) [24] and were previously used in the anal-
ysis of susceptibility to lower-respiratory tract infections (results
submitted for publication). They were individuals attending
general practice surgeries for reasons other than infection.
All controls included in this analysis were of self-reported
Caucasian ancestry from the United Kingdom. DNA was
extracted by Maxwell (Promega) at the Wellcome Trust Centre
for Human Genetics, University of Oxford.
Genotyping
The 3 exonic SNPs were successfully genotyped in 1839 sepsis
samples by using high-resolution melting analysis (HRMA),
with the assays described by Vossen et al [25]. Promoter
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polymorphism -221 genotypes for the sepsis samples were
mainly generated with the Affymetrix 5.0 genotyping chip
(N = 1477), as part of the genome-wide association study re-
ported elsewhere [6]. The rest of the sepsis samples (N = 369)
were genotyped by HRMA as above. All the healthy controls
(N = 477) were genotyped by HRMA. The genotypes of 19
samples were conﬁrmed using direct sequencing. Further
details of the genotyping techniques, quality control (QC) pro-
cedures, and sequencing can be found in the Supplementary
Information.
Statistical Analysis and Subgroups
Genotyping QC
Genotypes for all 4 SNPs obeyed Hardy–Weinberg equilibrium
with a P-value threshold of .05. The majority of the samples
have been genome-wide genotyped; therefore we were able to
exclude population outliers (40 individuals) and check for relat-
edness among individuals (no related individuals were detect-
ed). GWAS QC was performed as described elsewhere [6].
Possible Confounding Factors
Possible confounding factors were tested for their association
with outcome, using analysis of variance (for age) and the χ2
test (for other factors) in SPSS v18 (PASW Statistics 18). Age
associated signiﬁcantly with 28-day mortality from sepsis
(P = 6.25 × 10−21), whereas other possible confounding factors
such as gender (P = .697), CAP/peritonitis diagnosis (P = .191),
and presence of comorbid respiratory disease (P = .317) did
not. Therefore, age was included as a covariate in all the analyses.
Sepsis Outcome Analyses
All analyses were performed by logistic regression with age as a
covariate using SPSS v18 (PASW Statistics 18). We chose our
primary end-point for survival analyses as 28 days from ICU
admission, because most studies of sepsis patients have used
28-day mortality as the primary end-point to reﬂect “attribut-
able mortality” [26–28]. We also analyzed longer term survival
at 6 months. Although we included age as a covariate in the pri-
mary analyses, we also looked for associations in 2 groups of
younger patients (less than 70 and less than 60 years of age)
in whom it might be expected that MBL deﬁciency would
play a greater role. We performed analyses of associations
with outcome in the UK individuals only, to account for popu-
lation bias. In addition, we analyzed survival in the more homo-
geneous cohorts of patients with sepsis caused by CAP alone,
sepsis caused by peritonitis alone and CAP sepsis caused by
Streptococcus pneumoniae (the largest subgroup deﬁned by
organism).
Sepsis Susceptibility Analyses
In the susceptibility analyses, we included only UK patients
to compare to the UK controls and examined associations
with susceptibility to CAP sepsis and CAP sepsis caused by
S. pneumoniae.
Genotype Combinations Tested for Associations
We performed analyses deﬁning deﬁcient and sufﬁcient geno-
types in 3 different ways (by deﬁning O/O, XO/O and XA/O
combined genotypes, O/O, XO/O, XA/O and XA/XA combined
genotypes [16] or O/O, XO/O, XA/O and YA/O combined
genotypes [10] as MBL deﬁcient and all other combined geno-
types as MBL sufﬁcient). We also performed analyses for each
combined genotype compared to the wild-type YA/YA combined
genotype and for the distribution of all 6 combined genotypes
(O/O, XA/O, XA/XA, XA/YA, YA/O, and YA/YA). The allelic,
genotypic, recessive, dominant, and heterozygous tests were
also performed on each SNP individually, and on the AA, AO,
and OO combined exon genotypes.
Power Calculations
This study had 80% power to detect odds ratios (ORs) of 1.45,
1.57, and 1.52 or more in the analysis of 28 day survival, 6
month survival, and CAP sepsis susceptibility, respectively.
Even in our most underpowered subgroup (28 day survival in
those with pneumococcal CAP sepsis) we had 80% power to
detect ORs of 2.5 or more.
Correction for Multiple Testing
Because we have analyzed 4 SNPs in this study, Bonferroni cor-
rection gives a P-value threshold of .0125 for an association to
be declared signiﬁcant. Given that we have performed analyses
using many different models and phenotypes, however, this
correction may not be considered to be sufﬁciently stringent.
RESULTS
We recruited and analyzed 1839 patients with sepsis (983 with
CAP, 856 with peritonitis). The median APACHE score was 17
(range 2–44), and the mortality rate was 19.4%. The majority of
patients were recruited in the United Kingdom (Table 1).
Demographic and clinical characteristics of the enrolled pa-
tients (cases and controls) are shown in Table 1.
The observed allele frequencies in the sepsis cases and UK
controls were comparable to those observed in previously pub-
lished, large population-based European studies (Table 2)
[9, 29]. Age was included as a covariate in all analyses. The an-
tibiotics administered within the ﬁrst 24 hours were considered
to be adequate in 90.2% of cases, whereas in 6.5% of patients
initial antimicrobial treatment was considered to be inappropri-
ate and for 3.4% data was not available. There was no difference
in the proportion of patients receiving adequate antibiotic ther-
apy between survivors and nonsurvivors (P = .773) or between
individuals who were MBL sufﬁcient or deﬁcient (P = .275)
MBL2 Genetics and Sepsis • CID 2015:61 (1 September) • 697
(based on the most commonly used deﬁnition determined by
genotype combinations).
Survival Analysis
MBL2 genotype distributions for the main survival analyses are
presented in Table 3. MBL genotypic functional status (where the
O/O, XO/O, and XA/O combined genotypes were deﬁned as
MBL deﬁcient and all other combined genotypes as MBL
sufﬁcient) did not associate with 28-day mortality (P = .17),
6-month mortality (P = .23) or 28-day pneumococcal CAP mor-
tality (P = .64). No signiﬁcant associations were seen in any of the
other subgroups (P > .05 for all subgroups shown in Table 3).
The speciﬁc combinations of MBL genotypes that deﬁne
functional sufﬁciency or deﬁciency remain uncertain. There-
fore, we also performed sufﬁcient/deﬁcient analyses by deﬁning
genotypes XO/O, O/O, XA/O, and XA/XA [16] or XO/O, O/O,
XA/O, and YA/O [10] as MBL deﬁcient. There were no sig-
niﬁcant associations in the whole cohort or for any of the
subgroups shown in Table 3 (P > .05).
We also performed analyses of each genotype individually,
combined genotypes against each other and the exonic geno-
types only combined (A/A, A/O, O/O). Genotype frequencies
are listed for survivors and nonsurvivors for the main survival
subgroups analyzed in this cohort (Table 4). Across all these
survival analyses, the lowest observed nominal P-value was
.017 (Bonferroni corrected signiﬁcance threshold P = .0125),
for the promoter SNP heterozygous test in the peritonitis
28-day survival subgroup.
Susceptibility Analysis
Susceptibility analyses were performed only among the individ-
uals from the United Kingdom. CAP sepsis cases (N = 496) and
pneumococcal CAP sepsis cases (N = 95) were compared to
controls (N = 477) from the United Kingdom recruited within
the GRACE study. MBL2 genotype distributions for the cases
and controls in the susceptibility analyses are presented in
Table 5. MBL functional status did not associate with CAP sep-
sis susceptibility (P = .343) or with pneumococcal sepsis sus-
ceptibility (P = .587). As with the survival analyses, we also
analyzed functionally sufﬁcient/deﬁcient genotypes according
to their alternative deﬁnitions. There were no associations in
any of these susceptibility analyses (P > .05).
We also performed analyses of each genotype individually,
combined genotypes against each other and only the exonic ge-
notypes combined (A/A, A/O, O/O). Genotype frequencies are
listed for cases and controls in Table 6. Across these susceptibil-
ity analyses, the lowest observed nominal P-value was .029
Table 1. Demographic Data for Patients and Controls
Sepsis Cases
Control
Samples
N 1839 477
N deaths at 28 d 357 (19.4%) 0
Males 1069 (58.1%) 189 (39.6%)
Mean age (standard deviation) 64.2 (15.3) 49.2 (18.7)
N CAP 983 (53.5%) NA
N peritonitis 856 (46.5%) NA
APACHE II score; median (range) 17 (2–44) NA
S. pneumoniae identified
(CAP samples only)
245 (13.3%) NA
Respiratory disease 642 (34.9%) NA
COPD 296 (16.1%) 10 (2.1%)
Asthma 140 (7.6%) 59 (12.4%)
United Kingdom 831 447
Spain 228 NA
Belgium 155 NA
Germany 153 NA
Czech Republic 109 NA
Italy 97 NA
Poland 92 NA
France 59 NA
Ireland 54 NA
Estonia 22 NA
Serbia and Montenegro 21 NA
Greece 5 NA
Croatia 5 NA
Hungary 5 NA
Israel 2 NA
Netherlands 1 NA
Abbreviations: APACHE, Acute Physiology, Age, Chronic Health Evaluation;
CAP, community-acquired pneumonia; COPD, chronic obstructive
pulmonary disease; NA, not applicable.
Table 2. MBL2 Allele Frequencies in the Study Reported Here and 2 Large Published European Studies
Sepsis Cases UK Controls Dahl et al [29] Garcia-Laorden et al [9]
N samples 1839 477 9245 848 CAP 519 controls 1447 healthy controls
Country of samples Europe-wide UK Denmark Spain Spain Spain
B allele frequency 0.149 0.151 0.145 0.159 0.139 0.142
C allele frequency 0.019 0.024 0.017 0.022 0.031 0.029
D allele frequency 0.070 0.070 0.076 0.047 0.045 0.059
X allele frequency 0.219 0.203 Not genotyped 0.194 0.227 0.206
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Table 3. MBL Genotypic Functional Status and the Combined Genotype Distribution (−221 Promoter Single Nucleotide Polymorphism [SNP] and 3 Functional Exonic SNPs) Among
Survivors and Deaths in 28-day and 6-month Survival Analyses, and in 28-day Pneumococcal Survival Analysis
MBL
Functional
Status Genotypes
CAP and
Peritonitis
Sepsis 28 d
Deaths
CAP and
Peritonitis
Sepsis 28 d
Survivors
CAP Sepsis
28 day
Deaths
CAP Sepsis
28 d
Survivors
Peritonitis
Sepsis 28 d
Deaths
Peritonitis
Sepsis 28 d
Survivors
Pneumococcal
Sepsis 28 d
Deaths
Pneumococcal
Sepsis 28 d
Survivors
Sepsis 6
mo Deaths
Sepsis 6
mo
Survivors
MBL Deficient XO/O (%) 1 (0.3) 1 (0.1) 0 1 (0.1) 1 (0.6) 0 0 0 0 1 (0.1)
O/O (%) 19 (5.3) 81 (5.5) 6 (3.4) 43 (5.3) 13 (7.3) 38 (5.6) 2 (4.4) 11 (5.5) 12 (4.5) 35 (5.0)
XA/O (%) 30 (8.4) 162 (10.9) 18 (10.1) 84 (10.4) 12 (6.7) 78 (11.5) 5 (11.1) 24 (12.0) 28 (10.6) 73 (10.4)
Total (%) 50 (14.0) 244 (16.5) 24 (13.5) 128 (15.9) 26 (14.5) 116 (17.1) 7 (15.5) 35 (17.5) 40 (15.1) 109 (15.5)
MBL Sufficient XA/XA (%) 17 (4.8) 75 (5.0) 6 (3.4) 40 (5.0) 11 (6.1) 35 (5.2) 1 (2.2) 15 (7.5) 10 (3.8) 34 (4.8)
XA/YA (%) 74 (20.7) 355 (24.0) 42 (23.6) 198 (24.6) 32 (17.9) 157 (23.2) 12 (26.7) 40 (20.0) 67 (25.3) 166 (23.6)
YA/O (%) 98 (27.4) 381 (25.7) 48 (27.0) 211 (26.2) 50 (27.9) 170 (25.1) 9 (20.0) 57 (28.5) 68 (25.7) 189 (26.8)
YA/YA (%) 118 (33.1) 427 (28.8) 58 (32.6) 228 (28.3) 60 (33.5) 199 (29.4) 16 (35.6) 53 (26.5) 80 (30.2) 206 (29.3)
Total (%) 307 (86.0) 1238 (83.5) 154 (86.5) 677 (84.1) 153 (85.5) 561 (82.9) 38 (84.5) 165 (82.5) 225 (85) 595 (84.5)
Overall Total 357 1482 178 805 179 677 45 200 265 704
P Value for deficient/sufficient
status
.169 .198 .585 .643 .229
Percentages of genotype distributions in each patient group are shown in brackets. Analyses were also performed for 3 subgroups of CAP and peritonitis patients; those under 70, those under 60, and those from the UK.
None of the associations in these subgroups were significant (P-values .671, .235 and .870 respectively). The 2 detected XO/O genotypes both included one polymorphism in the −221 promoter, and B and D exonic
SNPs, and were confirmed by sequencing (Supplementary Figure 2). Association tests (performed by logistic regression with age as a covariate in SPSS version 18) for deficient/sufficient status were nonsignificant for
all subgroups.
Abbreviations: CAP, community-acquired pneumonia; MBL, mannose-binding lectin; SNP, single nucleotide polymorphism.
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(Bonferroni corrected signiﬁcance threshold P = .0125), for the
B exon SNP recessive test in the UK pneumococcal susceptibil-
ity subgroup.
DISCUSSION
We report a large, comprehensive analysis of associations
between the most extensively studied functional MBL2
polymorphisms and sepsis survival, as well as susceptibility to
CAP and pneumococcal pneumonia. Our large sample collec-
tion enabled us to also examine MBL2 genotype associations
with survival in a number of predeﬁned homogeneous
subgroups, including younger age groups, UK patients only, pa-
tients with CAP, those with pneumococcal pneumonia, and pa-
tients with peritonitis. Our ﬁndings strongly suggest that there
are no signiﬁcant, clinically meaningful associations between
Table 4. Exonic MBL2 Genotypes for the Main Survival Analysis Subgroups
MBL2 Genotype
Sepsis 28 d
Deaths
Sepsis 28 d
Survivors
Sepsis 6 mo
Deaths
Sepsis 6 mo
Survivors
Pneumococcal CAP
Sepsis 28 d Deaths
Pneumococcal CAP
Sepsis 28 d Survivors
A/A (%) 209 (58.5) 857 (57.8) 157 (59.2) 406 (57.7) 29 (64.4) 108 (54)
A/B (%) 81 (22.7) 336 (22.7) 58 (21.9) 164 (23.3) 8 (17.8) 46 (23)
A/C (%) 10 (2.8) 43 (2.9) 6 (2.3) 20 (2.8) 0 8 (4.0)
A/D (%) 37 (10.4) 164 (11.1) 32 (12.1) 78 (11.1) 6 (13.3) 27 (13.5)
Sum A/O (%) 128 (35.9) 543 (36.7) 96 (36.2) 262 (37.2) 14 (31.1) 81 (40.5)
B/B (%) 3 (0.8) 39 (2.6) 5 (1.9) 17 (2.4) 0 9 (4.5)
B/C (%) 2 (0.6) 5 (0.3) 0 0 0 0
B/D (%) 9 (2.5) 30 (2.0) 4 (1.5) 16 (2.3) 2 (4.4) 2 (1.0)
C/C (%) 0 1 (0.1) 0 1 (0.1) 0 0
C/D (%) 3 (0.8) 4 (0.3) 2 (0.8) 2 (0.3) 0 0
D/D (%) 3 (0.8) 3 (0.2) 1 (0.4) 0 0 0
Sum O/O (%) 20 (5.6) 82 (5.5) 12 (4.5) 36 (5.1) 2 (4.4) 11 (5.5)
Total 357 1482 265 704 45 200
P-value for AA,AO,OO
genotypic test
.937 .697 .488
Percentages of genotype distributions are shown in brackets. In addition to the genotypic test, we have also performed the allelic, recessive, dominant and
heterozygous tests for the AA, AO, OO genotypes, and all individual exonic SNPs (all P-values were nonsignificant following correction for multiple testing).
Abbreviations: CAP, community-acquired pneumonia; SNP, single nucleotide polymorphism.
Table 5. MBL Genotypic Functional Status and the Combined Genotype Distribution (−221 Promoter Single Nucleotide Polymorphism
[SNP] and 3 Functional Exonic SNPs) Among Cases and Controls From the United Kingdom in Community-Acquired Pneumonia (CAP)
Sepsis and Pneumococcal CAP Sepsis Susceptibility Analyses
MBL Functional Status Genotypes UK Controls UK CAP Sepsis Cases UK Pneumococcal CAP Sepsis Cases
MBL Deficient XO/O (%) 0 1 (0.2) 0
O/O (%) 19 (4.0) 27 (5.4) 6 (6.3)
XA/O (%) 57 (11.9) 45 (9.1) 12 (12.6)
Total (%) 76 (15.9) 73 (14.7) 18 (18.9)
MBL Sufficient XA/XA (%) 15 (3.1) 22 (4.4) 6 (6.3)
XA/YA (%) 107 (22.4) 128 (25.8) 21 (22.1)
YA/O (%) 139 (29.1) 128 (25.8) 22 (23.2)
YA/YA (%) 140 (29.4) 145 (29.2) 28 (29.5)
Total (%) 401 (84.0) 423 (85.2) 77 (81.1)
Overall Total 477 496 95
P Value for deficient/sufficient status
compared to controls
NA .343 .587
Percentages of genotype distributions are shown in brackets. Both detected XO/O genotypes included one polymorphism in the −221 promoter, B and D exonic
SNPs, and were confirmed by sequencing. Association tests (performed by logistic regression with age as a covariate in SPSS version 18) for deficient/sufficient
genotypes for each set of cases compared to the controls were nonsignificant.
Abbreviations: CAP, community-acquired pneumonia; MBL, mannose-binding lectin; NA, not applicable; SNP, single nucleotide polymorphism.
700 • CID 2015:61 (1 September) • Mills et al
MBL genotypes and either 28-day or 6-month survival from
sepsis, or susceptibility to CAP or pneumococcal pneumonia
in immune competent adults. The lowest P-value we observe
across all tests for all subgroups is .017 (for the promoter poly-
morphism heterozygous test in the peritonitis 28-day survival
subgroup). This cannot be considered a signiﬁcant result after
even a nonconservative correction for multiple testing. More-
over it is unlikely that population stratiﬁcation would have con-
founded our results as we were able to remove population
outliers from the analyses based on multidimensional-scaling
using genome-wide genotypes.
The effect ofMBL2 functional genetic variants has been stud-
ied extensively in a number of sepsis related phenotypes.
Garcia-Laorden et al [9] found, in one of the largest studies
(Table 2), that MBL2 genotypes do not associate with suscept-
ibility to CAP in adults, which is consistent with our ﬁndings.
They also concluded, as we did, that there was no association
between 28-day mortality and MBL2 deﬁcient genotypes.
They did, however, ﬁnd an association with 90-day survival.
Our 6-month survival analysis, however, does not support
such an association with longer term survival, even though
we have >99% power to detect an association with the OR
that they observed (OR = 2.34). Some members of our group
[30] have previously reported a study with a phenotype similar
to ours but recruited fewer samples (174 cases and 353 con-
trols). These investigators found an association between A/O
and O/O exonic polymorphisms and susceptibility to sepsis
and also showed an even more signiﬁcant association between
the distribution of combined genotypes and susceptibility to
sepsis. We did not replicate these ﬁndings in this larger sample
set.
Eisen et al [31] performed a meta-analysis of 6 studies of
MBL polymorphisms in patients with severe bacterial infection.
They found an association between low circulating levels
of MBL and mortality and an increased risk of death from
S. pneumoniae infection (OR = 5.62). We did not ﬁnd an
association between MBL2 deﬁcient genotypes and death
from sepsis due to S. pneumoniae infection, despite having
>99% power to ﬁnd an association of this strength. However,
Eisen et al also showed that MBL2 genotype is not a reliable
predictor of MBL levels, with the proportion of MBL deﬁcient
individuals being underestimated when deﬁned by genotype. It
is therefore possible that we did not capture all MBL deﬁcient
individuals, and that low MBL levels, rather than genotype,
might be associated with worse outcomes in our cohort. Never-
theless, our ﬁndings strongly suggest that a clinically relevant
relationship between MBL2 genotype and sepsis mortality in
immune competent adults is highly unlikely.
A more recent meta-analysis [8] found no evidence of an as-
sociation between exonic or promoter MBL2 variants and sus-
ceptibility to sepsis in adults. On the other hand, an association
was found between exonic polymorphisms and susceptibility to
sepsis in paediatric cases. Variant forms of MBL are very com-
mon in certain populations among healthy individuals [13], and
it is known that alternative immune mechanisms can replace
the function of MBL [32] thereby rendering deﬁcient individu-
als immune competent. This redundancy could explain the lack
of a signiﬁcant association between MBL2 functional polymor-
phisms and sepsis susceptibility and outcome in the present
study of immune competent adults. MBL plays a particularly
important role in host defense in individuals with a compro-
mised or immature adaptive immune system [7]. Our ﬁndings
do not exclude the possibility that MBL2 functional polymor-
phisms signiﬁcantly inﬂuence sepsis susceptibility and outcome
in these patient groups.
One of the limitations of our study is that the causal organism
was not identiﬁed in all cases. Without this information, we have
been unable to perform a complete analysis of bacterial and viral
subgroups. However, even with this information, subgroups de-
ﬁned by pathogens other than S. pneumoniae are likely to be too
small to have sufﬁcient power to detect an association.
We identiﬁed 2 individuals with variant alleles X, B, and D,
which were conﬁrmed by sequencing (Supplementary Figure 2).
Previous reports have suggested that due to linkage disequilibrium
Table 6. Exonic MBL2 Genotypes for the Susceptibility Analysis
Subgroups
MBL2 Genotype
UK
Controls
UK CAP
Sepsis
Cases
UK Pneumococcal
CAP Sepsis Cases
A/A (%) 262 (54.9) 295 (59.5) 55 (57.9)
A/B (%) 122 (25.6) 114 (23.0) 23 (24.2)
A/C (%) 20 (4.2) 10 (2.0) 2 (2.1)
A/D (%) 54 (11.3) 49 (9.9) 9 (9.5)
Sum A/O (%) 196 (41.1) 173 (34.9) 34 (35.8)
B/B (%) 6 (1.3) 13 (2.6) 5 (5.3)
B/C (%) 2 (0.4) 0 0
B/D (%) 8 (1.7) 10 (2.0) 1 (1.1)
C/C (%) 0 0 0
C/D (%) 1 (0.2) 4 (0.8) 0
D/D (%) 2 (0.4) 1 (0.2) 0
Sum O/O (%) 19 (4.0) 28 (5.6) 6 (6.4)
Total 477 496 95
P Value for AA,
AO,OO
genotypic test
NA .170 .530
Percentages of genotype distributions are shown in brackets. In addition to the
genotypic test, we have also performed the allelic, recessive, dominant and
heterozygous tests for the AA, AO, OO genotypes, and all individual exonic
SNPs (All P-values were nonsignificant following correction for multiple
testing).
Abbreviations: CAP, community-acquired pneumonia; NA, not applicable; SNP,
single nucleotide polymorphism.
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between the exon and promoter SNP, only the Y allele in the
promoter is present with exonic polymorphisms [9, 17]. Our
study shows that other combinations are also possible, although
they are very rare.
Although the inﬂuence of MBL levels and genotypes on sepsis
susceptibility and outcome have been extensively investigated,
most studies have been underpowered and therefore it is not sur-
prising that ﬁndings have been inconsistent. Moreover, it is well
recognized that performing meta-analyses using published data
are often limited by publication bias and hence an overestimation
of the importance of the SNP or SNPs of interest. In this study,
we found no signiﬁcant associations between MBL2 genotypes
and susceptibility to, or survival from sepsis in a sample set
that has adequate statistical power to show associations with
effect sizes previously reported in independent studies.
Supplementary Data
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(http://cid.oxfordjournals.org). Supplementary materials consist of data
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